Massachusetts General Hospital is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Location | Boston, MA, USA |
|---|---|
| Type | Research Hospital / Academic Medical Center |
| Founded | 1811 |
| Affiliation | Harvard Medical School |
| Website | [massgeneral.org](https://www.massgeneral.org/) |
Massachusetts General Hospital (Mass General) is the original and largest teaching hospital of Harvard Medical School, founded in 1811. Located in Boston, Massachusetts, Mass General is consistently ranked among the top hospitals in the United States and is a world-renowned center for biomedical research.
The hospital houses the MassGeneral Institute for Neurodegenerative Disease (MIND), one of the leading centers for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorder research in the world.
The MassGeneral Institute for Neurodegenerative Disease brings together researchers and clinicians working on:
| Disease Area | Research Focus |
|---|---|
| Alzheimer's Disease | Amyloid hypothesis, tau therapeutics, biomarkers, clinical trials |
| Parkinson's Disease | Alpha-synuclein, LRRK2, GBA, deep brain stimulation |
| ALS | SOD1, TDP-43, C9orf72, therapeutic screening |
| Frontotemporal Dementia | GRN, MAPT, TDP-43 pathology |
| Huntington's Disease | Genetic testing, symptomatic treatments |
Dr. Bradley Hyman was the Director of the MassGeneral Institute for Neurodegenerative Disease and a pioneering figure in Alzheimer's disease research. His contributions to understanding amyloid and tau pathology in AD were foundational to the field, and his work on disease mechanisms and therapeutic targets influenced generations of researchers.
Dr. John Growdon is a renowned neurologist specializing in movement disorders and Parkinson's disease. His work has advanced understanding of dopaminergic mechanisms and therapeutic approaches for PD.
Dr. Steven Arnold serves as Co-Director of the Alzheimer's Disease Research Center, leading clinical research programs and biomarker development initiatives.
The MassGeneral Institute for Neurodegenerative Disease brings together researchers and clinicians working on[1]:
Alzheimer's Disease Research
Parkinson's Disease and Movement Disorders
Amyotrophic Lateral Sclerosis (ALS)
Frontotemporal Dementia
Mass General maintains an extensive clinical trials infrastructure supporting trials across neurodegenerative diseases:
Active Trial Areas
Mass General offers world-class training:
The institution provides:
Mass General collaborates with:
The study of Massachusetts General Hospital has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Mass General has been at the forefront of neurodegenerative disease research for decades:
Alpha-Synuclein Discovery
The groundbreaking discovery that alpha-synuclein is the major component of Lewy bodies was made at Mass General[2:1], fundamentally changing understanding of Parkinson's disease pathogenesis and establishing the protein as a major therapeutic target.
Alzheimer's Disease Criteria
Mass General researchers helped develop the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria for diagnosing Alzheimer's disease, which incorporate biomarkers and represent a major advance in clinical diagnosis[8].
Biomarker Development
Mass General has pioneered development of cerebrospinal fluid and imaging biomarkers for AD and PD, enabling earlier diagnosis and better disease monitoring.
Current research priorities include:
Precision Medicine
Novel Therapeutic Targets
Emerging Technologies
New research initiatives focus on:
Selkoe DJ, et al. Alzheimer disease: Updated amyloid hypothesis and therapeutic approaches. Nat Rev Neurol. 2019. ↩︎
Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997. ↩︎ ↩︎
Chen X, et al. LRRK2 in Parkinson's disease: mechanisms and therapeutic targets. Nat Rev Neurol. 2019. ↩︎
Nalls MA, et al. Large-scale meta-analysis of Parkinson disease GWAS. Lancet Neurol. 2019. ↩︎
Taylor JP, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2022. ↩︎
Rascovsky K, et al. Diagnostic criteria for behavioral variant frontotemporal dementia. Brain. 2011. ↩︎
Gorno-Tempini ML, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011. ↩︎
Hyman BT, et al. National Institute on Aging-Alzheimer's Association criteria for the neuropathological assessment of Alzheimer's disease. Alzheimers Dement. 2012. ↩︎